Hanna Y Irie, MD, PhD
img_Hanna Y Irie
ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
ASSOCIATE PROFESSOR | Oncological Sciences
Are you a patient?
Cancer (Oncology)
Research Topics
Anti-Tumor Therapy, Cancer, Cell Biology, Cell Transformation, Growth Factors and Receptors, Protein Kinases

MD, Harvard Medical School

BA, Harvard University

Clinical Fellow, Dana-Farber Cancer Institute

Instructor, Dana-Farber Cancer Institute/Harvard Medical School

Intern/Resident, Massachusetts General Hospital

MD, Harvard Medical School

PhD, Harvard Medical School

Research Fellow, Harvard Medical School

Residency, Internal Medicine, Massachusetts General Hospital

Fellowship, Hematology & Oncology, Dana-Farber Cancer Institute


Breast Cancer Alliance Exceptional Project Grant

Breast Cancer Alliance


Breast Cancer Research Foundation Grant

Breast Cancer Research Foundation


AACR-Genentech BioOncology Career Development Award for Research on the Her Family in Cancer



Susan G Komen Career Catalyst Award

Susan G Komen for the Cure


Dana Farber Cancer Institute SPORE in Breast Cancer Career Development Award



Terri Brodeur Breast Cancer Research Foundation Grant

Terri Brodeur Breast Cancer Research Foundation


AACR Scholar-in-Training Award

American Assocaition for Cancer Research


K08 Mentored Clinical Scientist Award



ASCO Young Investigator Award

American Society for Clinical Oncology

Cancer Precision Medicine Retreat -- Session 6: Hanna Yoko Irie

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Irie did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.